Nivolumab - Latest Advances

A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab.

Journal: Future oncology (London, England)

Published: December 12, 2025

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Journal: Future oncology (London, England)

Published: December 10, 2025

Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.

Journal: Immuno-oncology technology

Published: December 09, 2025

Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).

Journal: JCO oncology advances

Published: December 08, 2025

Adverse reactions of PD-1/PD-L1 inhibitors in cancer: FEARS database analysis and protocols to mitigate immune-related events in elderly patients and when using pembrolizumab and atezolizumab.

Journal: International journal of clinical pharmacology and therapeutics

Published: December 05, 2025

The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability.

Journal: Expert review of clinical pharmacology

Published: December 04, 2025

Reply to: "Comment on nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration".

Journal: Journal of hepatology

Published: December 02, 2025

Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors.

Journal: Renal failure

Published: November 25, 2025

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

Retrospective Analysis of Nivolumab-Induced Isolated Adrenocorticotropin Deficiency.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

Published: November 24, 2025

Complete response to nivolumab in a patient with HPV-associated squamous cell carcinoma of the anus: the predictive value of tumour-infiltrating CD8+PD-1+ T cells.

Journal: European journal of dermatology : EJD

Published: November 24, 2025

Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.

Journal: The New England journal of medicine

Published: November 19, 2025

Filters

A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab.

A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab.

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.

Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.

Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).

Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).

Adverse reactions of PD-1/PD-L1 inhibitors in cancer: FEARS database analysis and protocols to mitigate immune-related events in elderly patients and when using pembrolizumab and atezolizumab.

Adverse reactions of PD-1/PD-L1 inhibitors in cancer: FEARS database analysis and protocols to mitigate immune-related events in elderly patients and when using pembrolizumab and atezolizumab.

The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability.

The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability.

Reply to: "Comment on nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration".

Reply to: "Comment on nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration".

Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors.

Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors.

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.

Retrospective Analysis of Nivolumab-Induced Isolated Adrenocorticotropin Deficiency.

Retrospective Analysis of Nivolumab-Induced Isolated Adrenocorticotropin Deficiency.

Complete response to nivolumab in a patient with HPV-associated squamous cell carcinoma of the anus: the predictive value of tumour-infiltrating CD8+PD-1+ T cells.

Complete response to nivolumab in a patient with HPV-associated squamous cell carcinoma of the anus: the predictive value of tumour-infiltrating CD8+PD-1+ T cells.

Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.

Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.